Global X - S&P Biotech ETF
Global X - S&P Biotech ETF Fundamental Analysis
Global X - S&P Biotech ETF (CURE.AX) shows weak financial fundamentals with a PE ratio of N/A, profit margin of 0.00%, and ROE of 0.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 25.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CURE.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakCURE.AX struggles to generate sufficient returns from assets.
Valuation Score
WeakCURE.AX trades at a premium to fair value.
Growth Score
WeakCURE.AX faces weak or negative growth trends.
Financial Health Score
ModerateCURE.AX shows balanced financial health with some risks.
Profitability Score
WeakCURE.AX struggles to sustain strong margins.
Key Financial Metrics
Is CURE.AX Expensive or Cheap?
Debt/Equity
Global X - S&P Biotech ETF has a debt-to-equity ratio of 0.00, indicating its leverage.
How Well Does CURE.AX Make Money?
Net Profit Margin
For every $100 in sales, Global X - S&P Biotech ETF keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.00 in profit for every $100 of shareholder equity.
ROA
Global X - S&P Biotech ETF generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
N/A
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
N/A
vs 25 benchmark
P/B Ratio
Price to book value ratio
N/A
vs 25 benchmark
P/S Ratio
Price to sales ratio
N/A
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.00
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How CURE.AX Stacks Against Its Sector Peers
| Metric | CURE.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | N/A | 18.83 | N/A |
| ROE | 0.00% | 817.00% | Weak |
| Net Margin | 0.00% | 1784.00% | Weak |
| Debt/Equity | 0.00 | 0.99 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 661.85 | Weak Liquidity |
| ROA | 0.00% | -23754.00% (disorted) | Weak |
CURE.AX outperforms its industry in 1 out of 5 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Global X - S&P Biotech ETF's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical